Pain Therapeutics conference will be
remote access only. In order to attend this event
PRE-REGISTRATION IS REQUIRED on the ASDEvents website, which is subject to final approval by the conference organizer.
The Global
Pain Therapeutics Market was valued at $11.26 Million in 2018 and is projected to reach $15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Improving pain management continues to be a priory as pain-derived disabilities such as osteoarthritis, back pain, migraines and cancer are leading cause of disability worldwide. Yet, pain treatment remains the biggest clinical burden of the age as a result of lack of efficacy, increasing side effects and the opioid crisis that is now entering Europe following its epidemic in the USA.
The 20th Annual Conference will overview the current state of pain treatment highlighting clinical success to date as well as evaluating the potential of drug candidates in the pipelines.
Join Europe's leading
Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and research institutions. Discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.
Benefits of Attending
- Network with leading pharmaceutical companies and academic researchers of the pain community including GSK, Centrexion, Grunenthal Group, Mundipharma Research Limited, UCL, Janssen, University of Edinburgh and many more!
- Rethink pain research by exploring novel biomarkers, sex differences in nociception, pain clinical trial design and novel targets
- Learn about the struggles of opioid-based treatments and explore the current stages of clinical research with non-opioid targets such as; cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors
- Improve your understanding of neuro-immune interactions and their role in pain pathology, a promising new angle of pain research
Who should attend
Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Departments, Principal Research Scientists, Clinical Lead, Clinical Operations in the following fields:
- Pain and Migraine
- Pain Innovation R&D
- Neuroscience
- CNS
- Neuropathic Pain
- Analgesic clinical development
- Anesthesia and Pain Management
- CNS clinical trials
- Translational science
- Drug development
- Discovery Medicine
- Exploratory development
- Clinical and pharmaceutical operations
- Medical Affairs
Featured 2020 Speakers:
- Carole Torsney, Senior Lecturer, University of Edinburgh
- Cristina Cosi, Senior Scientist Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
- Domenico Merante, VP Clinical Development, Independent
- Edward Emery, Investigator, GSK
- James Campbell, Chief Scientific Officer , Centrexion Therapeutics Corp
- Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
- Joop van Griensven, President , Pain Alliance Europe (PAE)
- Joshua M. Cohen, Global Medical Lead for Migraine & Headache, Teva Pharmaceuticals
- Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
- Mark J Field, Owner/Founder, Analgesic Innovation
- Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
- Paul Ratcliffe, Vice President, Setup Innovation Hubs , Grunenthal Group
- Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
- Sandrine Geranton, Senior Research Fellow, UCL Institute of Ophthalmology
- Stephen Hunt, Professor, UCL
- Tanja Ouimet, Head of Clinical Operations, Pharmaleads
- Theo Meert, Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
- Zahid Ali, Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
